Brief: Genocea Sees Longer-Term Efficacy In Combination With Checkpoint Inhibitor For GEN-009 Neoantigen Vaccine In Q2
04/01/2021 22:32
Jan 4 (Reuters) - Genocea Biosciences Inc GNCA.O :
* GENOCEA BIOSCIENCES SAYS SEES LONGER TERM EFFICACY IN
COMBINATION WITH CHECKPOINT INHIBITOR FOR GEN-009 NEOANTIGEN
VACCINE IN Q2 2021 - PRESENTATION
* GENOCEA BIOSCIENCES SAYS SEES MONOTHERAPY EFFICACY IN
CHECKPOINT-RESISTANT PATIENTS FOR GEN-011 NEOANTIGEN CELL
THERAPY IN LATE Q4 2021 OR Q1 2022
Source text: (https://bit.ly/3pNCeYj)
Further company coverage: GNCA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genocea Biosciences
See all newsBluebird, Chimerix, Clovis have under 6 months of cash left - Truist
Genocea Biosciences plunges as it winds down operations
Brief: Genocea Announces Wind Down Of Operations And Delisting From Nasdaq
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Oppenheimer Holdings, IES Holdings Inc, Avantor Inc